YU62096A - Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof - Google Patents

Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof

Info

Publication number
YU62096A
YU62096A YU62096A YU62096A YU62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A YU 62096 A YU62096 A YU 62096A
Authority
YU
Yugoslavia
Prior art keywords
polyethylene oxide
procedure
preparation
application
pharmaceutical formulation
Prior art date
Application number
YU62096A
Other languages
Serbo-Croatian (sh)
Inventor
Ross James Macrae
Janet Sarah Smith
Original Assignee
Pfizer Research And Development Company N.V./S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Research And Development Company N.V./S.A. filed Critical Pfizer Research And Development Company N.V./S.A.
Publication of YU62096A publication Critical patent/YU62096A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Opisani pronalazak odnosi se na kontrolisano-otpuštajuće farmaceutske formulacije koje se sastoje od aktivne komponente, polietilenoksida niske molekulske mase, hidroksipropilmetilceluloze, ekscipijenata za tabletiranje i, po potrebi, od jednog ili više enteričnih polimera formulacije ovog pronalaska daju konstantnu brzinu otpuštanja leka u in vitro modelima gastrointestinalnog trakta. Takođe je opisana primena polietilenoksida niske molekulske mase u tim formulacijama, kao i postupak za njihovu proizvodnju.The present invention relates to controlled-release pharmaceutical formulations comprising the active ingredient, low molecular weight polyethylene oxide, hydroxypropylmethylcellulose, tableting excipients and, optionally, one or more enteric polymers. gastrointestinal tract. The use of low molecular weight polyethylene oxides in these formulations is also described, as well as a process for their production.

YU62096A 1995-11-21 1996-11-20 Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof YU62096A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9523752.5A GB9523752D0 (en) 1995-11-21 1995-11-21 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
YU62096A true YU62096A (en) 1999-03-04

Family

ID=10784188

Family Applications (1)

Application Number Title Priority Date Filing Date
YU62096A YU62096A (en) 1995-11-21 1996-11-20 Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof

Country Status (29)

Country Link
EP (1) EP0862437A1 (en)
JP (1) JPH10513481A (en)
KR (1) KR19990071505A (en)
CN (1) CN1215993A (en)
AP (1) AP718A (en)
AR (1) AR004335A1 (en)
AU (1) AU709560B2 (en)
BG (1) BG102438A (en)
BR (1) BR9611626A (en)
CA (1) CA2232715A1 (en)
CO (1) CO4480020A1 (en)
CZ (1) CZ155498A3 (en)
GB (1) GB9523752D0 (en)
HR (1) HRP960554A2 (en)
HU (1) HUP9903734A3 (en)
IS (1) IS4706A (en)
MA (1) MA26410A1 (en)
MX (1) MX9804008A (en)
NO (1) NO982302L (en)
NZ (1) NZ322053A (en)
OA (1) OA10687A (en)
PE (1) PE22898A1 (en)
PL (1) PL326981A1 (en)
SK (1) SK63098A3 (en)
TN (1) TNSN96141A1 (en)
TR (1) TR199800902T2 (en)
WO (1) WO1997018814A1 (en)
YU (1) YU62096A (en)
ZA (1) ZA969722B (en)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69833671T2 (en) * 1997-12-16 2006-11-30 Pfizer Products Inc., Groton COMBINATION OF AN ALPHA-1 ADRENORE RECEPTOR ANTAGONIST AND A CGM PDEV HEMMER TO TREAT IMPOTENCE
EA003101B1 (en) 1998-03-19 2002-12-26 Бристол-Майерз Сквибб Компани Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (en) * 1998-05-15 2000-10-14 Pfizer PHARMACEUTICAL FORMULATIONS.
EP0987020A1 (en) * 1998-09-04 2000-03-22 Pharma Pass LLC Metoprolol composition and processes for manufacturing the same
EP0974343B1 (en) * 1998-07-22 2004-09-29 Pharma Pass II LLC Process for manufacturing a solid metoprolol composition
CO5140079A1 (en) * 1998-10-14 2002-03-22 Novartis Ag PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en) 1998-10-23 2004-07-15 Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А. CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) * 2001-09-14 2003-03-27 Pawan Seth Pharmaceutical composition comprising doxasozin
TWI312285B (en) 2001-10-25 2009-07-21 Depomed Inc Methods of treatment using a gastric retained gabapentin dosage
US7612112B2 (en) 2001-10-25 2009-11-03 Depomed, Inc. Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) * 2001-10-25 2004-04-20 Depomed, Inc. Optimal polymer mixtures for gastric retentive tablets
US8329217B2 (en) 2001-11-06 2012-12-11 Osmotica Kereskedelmi Es Szolgaltato Kft Dual controlled release dosage form
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
EP1680078A2 (en) * 2003-10-17 2006-07-19 Ranbaxy Laboratories, Ltd. Oral matrix formulations of doxazosin
US20050255157A1 (en) * 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) * 2004-05-28 2006-04-27 한미약품 주식회사 Sustained release composition for oral administration of niacin
DE102004054054A1 (en) 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) * 2004-11-20 2007-02-07 대우약품공업주식회사 A sustained release tablet comprising doxazosin
AU2006284053B2 (en) * 2005-08-22 2010-04-22 Novartis Ag Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20090176882A1 (en) 2008-12-09 2009-07-09 Depomed, Inc. Gastric retentive gabapentin dosage forms and methods for using same
MX2008013675A (en) 2006-04-26 2009-03-06 Supernus Pharmaceuticals Inc Controlled released preparations of oxcarbazepine having sigmoidal release profile.
CN109503584A (en) 2006-05-04 2019-03-22 勃林格殷格翰国际有限公司 Polymorphic
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
CN100396282C (en) * 2006-07-25 2008-06-25 山东省医药工业研究所 Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
MX2010009990A (en) 2008-03-11 2010-12-15 Depomed Inc Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic.
US8372432B2 (en) 2008-03-11 2013-02-12 Depomed, Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20091730A1 (en) 2008-04-03 2009-12-10 Boehringer Ingelheim Int FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh DPP-4 INHIBITOR AND ITS USE
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en) 2008-12-17 2010-12-24 동아제약주식회사 The controlled released pharmaceutical compsitions of udenafil for sustained release property
PL2395983T3 (en) 2009-02-13 2020-09-07 Boehringer Ingelheim International Gmbh Pharmaceutical composition comprisng a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
AU2010239311B2 (en) 2009-04-20 2014-05-22 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
US8828953B2 (en) 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
US9901551B2 (en) 2009-04-20 2018-02-27 Ambra Bioscience Llc Chemosensory receptor ligand-based therapies
MX364651B (en) 2009-11-27 2019-05-03 Boehringer Ingelheim Int Gmbh Star Treatment of genotyped diabetic patients with dpp-iv inhibitors such as linagliptin.
US9198861B2 (en) 2009-12-22 2015-12-01 Mallinckrodt Llc Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) * 2009-12-22 2011-06-23 Mallinkckrodt Inc. Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
EP2566469B1 (en) 2010-05-05 2022-12-21 Boehringer Ingelheim International GmbH Combination therapy
MX342120B (en) 2010-07-09 2016-09-14 William Owen Wilkison Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin.
KR20140114736A (en) 2010-10-19 2014-09-29 엘셀릭스 테라퓨틱스 인코포레이티드 Chemosensory receptor ligand-based therapies
AR083878A1 (en) 2010-11-15 2013-03-27 Boehringer Ingelheim Int VASOPROTECTORA AND CARDIOPROTECTORA ANTIDIABETIC THERAPY, LINAGLIPTINA, TREATMENT METHOD
RS61153B1 (en) 2011-01-07 2020-12-31 Anji Pharma Us Llc Chemosensory receptor ligand-based therapies
CN102058555A (en) * 2011-01-13 2011-05-18 北京汇诚瑞祥医药技术有限公司 Doxazosin controlled release tablet
UY33937A (en) 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN102188431A (en) * 2011-05-09 2011-09-21 浙江九旭药业有限公司 Doxazosin mesylate sustained-release tablets and preparation method thereof
US8858963B1 (en) 2011-05-17 2014-10-14 Mallinckrodt Llc Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US8658631B1 (en) 2011-05-17 2014-02-25 Mallinckrodt Llc Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8741885B1 (en) 2011-05-17 2014-06-03 Mallinckrodt Llc Gastric retentive extended release pharmaceutical compositions
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
WO2013158928A2 (en) 2012-04-18 2013-10-24 Elcelyx Therapeutics, Inc. Chemosensory receptor ligand-based therapies
WO2013171167A1 (en) 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
EP3878445A3 (en) 2013-06-05 2021-10-27 Synchroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
WO2015128453A1 (en) 2014-02-28 2015-09-03 Boehringer Ingelheim International Gmbh Medical use of a dpp-4 inhibitor
CN105616378A (en) * 2014-10-31 2016-06-01 康普药业股份有限公司 Fluconazole capsule and preparation method therefor
WO2017211979A1 (en) 2016-06-10 2017-12-14 Boehringer Ingelheim International Gmbh Combinations of linagliptin and metformin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1198386B (en) * 1982-07-06 1988-12-21 Lepetit Spa A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
US4837111A (en) * 1988-03-21 1989-06-06 Alza Corporation Dosage form for dispensing drug for human therapy
IL92966A (en) * 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
PT98374A (en) * 1990-07-23 1994-01-31 Alza Corp OSMOTIC DEVICE FOR NICOTINE SYSTEMIC ADMINISTRATION AND NICOTINE BASED PROCESS

Also Published As

Publication number Publication date
CN1215993A (en) 1999-05-05
MA26410A1 (en) 2004-12-20
NZ322053A (en) 1999-11-29
HRP960554A2 (en) 1998-02-28
NO982302D0 (en) 1998-05-20
NO982302L (en) 1998-07-17
CA2232715A1 (en) 1997-05-29
TNSN96141A1 (en) 2005-03-15
AU709560B2 (en) 1999-09-02
OA10687A (en) 2002-11-27
GB9523752D0 (en) 1996-01-24
AU7572196A (en) 1997-06-11
HUP9903734A3 (en) 2000-04-28
MX9804008A (en) 1998-09-30
CZ155498A3 (en) 1999-03-17
TR199800902T2 (en) 1998-09-21
PE22898A1 (en) 1998-05-07
ZA969722B (en) 1998-05-20
BG102438A (en) 1999-01-29
AP718A (en) 1999-01-06
HUP9903734A2 (en) 2000-03-28
JPH10513481A (en) 1998-12-22
KR19990071505A (en) 1999-09-27
AP9600883A0 (en) 1997-01-31
EP0862437A1 (en) 1998-09-09
SK63098A3 (en) 1999-05-07
IS4706A (en) 1998-03-31
PL326981A1 (en) 1998-11-09
BR9611626A (en) 1999-06-01
AR004335A1 (en) 1998-11-04
WO1997018814A1 (en) 1997-05-29
CO4480020A1 (en) 1997-07-09

Similar Documents

Publication Publication Date Title
YU62096A (en) Sustained released pharmaceutical formulation, the application of polyethylene oxide in them and procedure for the preparation thereof
YU49698A (en) Tetrahydrolipstatin containing compositions
RS50303B (en) Controlled release pharmaceutical composition comprising nimesulide
ATE329608T1 (en) FORMULATIONS OF COPOLYMER 1 (GLATIRAMER ACETATE) FOR ORAL, NASAL AND PULMONARY ADMINISTRATION
HUP0302319A2 (en) Pharmaceutical compositions for the oral delivery of pharmacologically active agents
AR023972A1 (en) COMPOSITIONS OF MEDICINES BASED ON ANTI-POLINERGICALLY ACTIVE AND BETA-MIMETIC COMPOUNDS
RS50937B (en) Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
HUP0004383A2 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
AR037260A1 (en) FORMULATIONS OF WATER SUSTAINED RELEASE PROTEINS
ES2082723B1 (en) PHARMACEUTICAL FORMULATION OF FLUOXETINE IN A DISPERSIBLE FORM.
HRP20020088B1 (en) Levodopa/carbidopa/entacapone pharmaceutical preparation
ME00330B (en) Once-a-day oxycodone formulations
DE60326709D1 (en) PHARMACEUTICAL FORMULATIONS WITH IMPROVED BIOAVAILABILITY
ME00637B (en) Compositions containing diphosphonic acids
RS49890B (en) High molecular weight medicine-containing preparation in powder form for administration through mucosa
BR0209283A (en) Method for the manufacture of a low dosage pharmaceutical composition having uniform drug distribution and potency
AR011919A1 (en) FORMULATION IN TABLETS OR SWALLOWING CAPSULES OF PARACETAMOL (N-ACETIL-P-AMINOFENOL) AND PROCEDURE TO PREPARE IT
IS7006A (en) Dihydrogen 3-piperidinopropiophenone and medicinal products containing said compounds
HUP0301390A2 (en) Oral pharmaceutical composition containing valsartan
BR0115989A (en) A pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient.
EE03740B1 (en) A modified release oral 5-ASA pharmaceutical composition for the treatment of intestinal diseases
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
MXPA02011533A (en) NOVEL FORMULATIONS OF agr; 2, 4 DISULFOPHENYL N TERT BUTYLNITRONE.
CA2255064A1 (en) Potassium, sodium and tris oxaprozin salt pharmaceutical formulations
HUP9901659A2 (en) Use of flupirtin for producing pharmaceutical compositions suitable for the prevention and treatment of diseases which are associated with damage to the haemopoietic cell system